Premium
Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma
Author(s) -
Lebo Nicole L.,
Griffiths Rebecca,
Hall Stephen,
Dimitroulakos Jim,
JohnsonObaseki Stephanie
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25152
Subject(s) - medicine , head and neck squamous cell carcinoma , hazard ratio , oncology , statin , head and neck cancer , confidence interval , retrospective cohort study , larynx , cancer , cohort , basal cell , surgery
Background Preclinical and early‐phase clinical studies have suggested an oncoprotective role of statins in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to determine whether incidental statin use in patients with human papillomavirus (HPV)‐negative HNSCC is predictive of improved oncologic outcomes. Methods A retrospective cohort study of 1194 patients from the Ontario Cancer Registry diagnosed with HNSCC from 2007 to 2012 was performed using linked databases from the Institute for Clinical Evaluative Sciences. Overall survival (OS) and disease‐specific survival (DSS) were compared between patients taking statins and controls. Results Patients with statin exposure demonstrated improved OS (hazard ratio [HR] 0.758; P = .0011; 95% confidence interval [CI] 0.642‐0.896), and DSS (HR 0.693; P = .0040; 95% CI 0.539‐0.889) compared with those not on statins at the time of diagnosis. Conclusion Incidental statin use at the time of diagnosis of HPV‐negative squamous cell carcinoma (SCC) of the larynx, hypopharynx, and nasopharynx demonstrated improved OS and DSS.